Matever (Levetiracetam)

Levetiracetam is an antiepileptic medication used to control seizure activity in various epilepsy syndromes.

• Partial‑onset seizures: Decreases the number of focal seizure episodes in patients with epilepsy, improving seizure control when used as monotherapy or adjunct therapy.
• Generalized tonic‑clonic seizures: Helps prevent the occurrence of bilateral convulsive seizures, contributing to overall seizure reduction in individuals with generalized epilepsy.
• Myoclonic seizures: Lowers the frequency of sudden, brief muscle jerks characteristic of myoclonic epilepsy, supporting better daily functioning.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, stabilizing neuronal membranes and diminishing hyper‑excitability. By reducing the release of excitatory neurotransmitters, the drug lowers the likelihood of synchronized neuronal firing that underlies seizure generation.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Somnolence: increased sleepiness or fatigue.
• Headache: mild to moderate head pain.
• Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Psychiatric changes: depression, anxiety, or suicidal thoughts.
• Blood disorders: thrombocytopenia or leukopenia.
• Rash with systemic involvement: Stevens‑Johnson syndrome.

When prescribing levetiracetam, clinicians should consider several safety considerations to optimize patient outcomes.

• Renal function: Adjust dose in patients with impaired renal clearance, as the drug is primarily excreted unchanged.
• Pregnancy and lactation: Use only if potential benefit outweighs risk; limited data are available.
• Psychiatric history: Monitor for mood changes, depression, or suicidal ideation, especially in susceptible individuals.
• Drug interactions: Review concomitant medications for potential interactions that may affect seizure control.
• Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and direct light.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Carbamazepine: may lower levetiracetam plasma concentrations.
• Phenobarbital: can reduce levetiracetam effectiveness.
• Phenytoin: may decrease levetiracetam levels.

Moderate Interactions (Monitor Closely)

• Alcohol: can enhance central nervous system depression.
• Other antiepileptics: dose adjustments may be needed when combined.
• Renally cleared drugs: monitor renal function to prevent accumulation.